Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Related GSK
Glaxo, Genmab Report Positive Interim Result for Phase III Study of Ofatumumab
Markets Little Changed Ahead Of The Federal Reserve's Policy Decision
Bayer Buys Merck Consumer Care Unit (Fox Business)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Most Popular

Related Articles (THRX + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters